Results 141 to 150 of about 256,231 (309)

Ursolic acid sensitizes cisplatin-resistant HepG2/DDP cells to cisplatin via inhibiting Nrf2/ARE pathway

open access: yes, 2016
Shouhai Wu,1,2 Tianpeng Zhang,1 Jingsheng Du3 1School of Life Sciences, Sun Yat-sen University, 2Center for Regenerative and Translational Medicine, 3Department of Pharmacy, The Second Affiliated Hospital, Guangzhou University of Chinese Medicine ...
Zhang T, Wu S, Du J
core  

Advances in Cancer Immunotherapy for Solid Tumors

open access: yesAdvanced Science, EarlyView.
Cancer immunotherapy for solid tumors is rapidly evolving beyond classical checkpoint blockade toward more precise strategies. Emerging checkpoint targets, bispecific antibodies, antibody–drug conjugate combinations, personalized vaccines, cellular therapies, and engineered cytokines are expanding therapeutic possibilities, while biomarker‐guided ...
Shira Gabizon‐Peretz   +1 more
wiley   +1 more source

Molecular mechanisms of cisplatin resistance in cervical cancer

open access: yes, 2016
Haiyan Zhu, Hui Luo, Wenwen Zhang, Zhaojun Shen, Xiaoli Hu, Xueqiong Zhu Department of Obstetrics and Gynecology, The Second Affiliated Hospital of Wenzhou Medical University, Wenzhou, People’s Republic of China Abstract: Patients with advanced ...
Zhang W   +5 more
core  

FOS3D: A Fluorescence‐Enabled Toolkit for Characterizing a Three‐dimensional Osteosarcoma Model

open access: yesAdvanced Science, EarlyView.
FOS3D describes fluorescent (F) osteosarcoma (OS) cells in a tri‐dimensional (3D) model. The study comprises three phases: development, where biofabrication parameters are tuned to achieve cytocompatibility and tumor‐specific mechanical properties in cell‐laden gelatin methacryloyl constructs; validation, where whole‐well fluorescence reading is ...
William Humble   +9 more
wiley   +1 more source

Surfaceome Reprogramming of Stemsomes Promotes Lung Cancer Targeting via Potentiated Receptor–Ligand Interactions

open access: yesAdvanced Science, EarlyView.
This study presents a surfaceome‐reprogramming strategy for mutation‐independent lung cancer therapy by repurposing dexamethasone to prime mesenchymal stem cell‐derived nanovesicles. The engineered vesicles leverage multi‐valent interactions mediated by upregulated adhesion proteins, EPHA2, and NOTCH3.
Geunhye Kim   +8 more
wiley   +1 more source

Cisplatin induces protective autophagy through activation of BECN1 in human bladder cancer cells

open access: yes, 2017
Ji-Fan Lin,1 Yi-Chia Lin,2 Te-Fu Tsai,2,3 Hung-En Chen,2 Kuang-Yu Chou,2,3 Thomas I-Sheng Hwang2–4 1Central Laboratory, Shin Kong Wu Ho-Su Memorial Hospital, Taipei, 2Division of Urology, School of Medicine, Fu-Jen Catholic University, New Taipei,
Lin JF   +5 more
core  

Comparison Between Upfront Surgery and Preoperative Chemotherapy for CY1P0 Gastric Cancer: A Japanese Sub‐Analysis of CONVO‐GC‐1

open access: yesAnnals of Gastroenterological Surgery, EarlyView.
ABSTRACT Background Radical gastrectomy, followed by adjuvant chemotherapy has been a common practice in Japan for peritoneal lavage cytology‐positive (CY1) but peritoneal dissemination‐negative (P0) stage IV gastric cancer. This study aimed to clarify the differences in treatment outcomes between upfront surgery and preoperative chemotherapy, followed
Kenichiro Furukawa   +12 more
wiley   +1 more source

A Deep‐Red‐Absorbing Osmium(II) Complex as a Photosensitizer for Photodynamic Therapy Inducing Immunogenic Cell Death

open access: yesAngewandte Chemie, EarlyView.
A deep‐red‐excited osmium(II) photosensitizer (Os2) induces immunogenic cell death (ICD) under 740 nm irradiation and triggers robust anti‐tumor immune responses both in vitro and in vivo. ABSTRACT Immunogenic cell death (ICD), which converts tumor cells into their own vaccine, plays a pivotal role in the development of novel anticancer therapies. Here,
Yiyi Zhang   +12 more
wiley   +2 more sources

Essential Updates 2024–2025: Surgical Strategy for Esophageal Cancer Toward a New Paradigm in the Era of Immunotherapy and Personalization

open access: yesAnnals of Gastroenterological Surgery, EarlyView.
This review summarizes key advances from 2024 to 2025 that are reshaping esophageal cancer surgery toward a strategy‐oriented, personalized paradigm through the integration of immunotherapy, population aging, and intelligent technologies. Adjuvant nivolumab after neoadjuvant chemoradiotherapy remains the only perioperative approach with durable benefit,
Shuichiro Oya   +2 more
wiley   +1 more source

Survival Outcomes of Gemcitabine–Cisplatin–S‐1 Versus Gemcitabine–Cisplatin in Unresectable Biliary Tract Cancer: A Multicenter Retrospective Study With a Focus on Conversion Surgery

open access: yesAnnals of Gastroenterological Surgery, EarlyView.
In this multicenter retrospective study conducted by the Biliary Tract Club, we compared survival outcomes between gemcitabine–cisplatin–S‐1 (GCS) and gemcitabine–cisplatin (GC) in patients with unresectable biliary tract cancer, with a particular focus on conversion surgery. GCS was associated with longer overall and progression‐free survival compared
Hisashi Kosaka   +27 more
wiley   +1 more source

Home - About - Disclaimer - Privacy